Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results
September 23 2015 - 10:26AM
Dow Jones News
By Tess Stynes
Amgen Inc. and Allergan PLC said their investigational
biosimilar treatment for advanced lung cancer demonstrated clinical
equivalence in safety and effectiveness compared with Roche Holding
AG's Avastin.
The investigational biosimilar for advanced nonsquamous nonsmall
cell lung cancer--called ABP 215--is being developed as a
biosimilar to bevacizumab, which is marketed under the brand name
Avastin.
Amgen's head of research and development Sean Harper said in
prepared remarks Wednesday that nonsmall-cell lung cancer is the
leading cause of cancer deaths in the U.S. and the European Union
among both men and women.
The introduction of biosimilar drugs in the U.S., which kicked
off this month with Novartis AG's version of an Amgen Inc.
blockbuster, is expected to provide options to battle rising drug
prices, which have been drawing increasing criticism.
Amgen and Allergan are collaborating on four biosimilar cancer
treatments while both drug makers are developing biosimilar
treatments separately.
Earlier this year, Amgen's investigational biosimilar treatment
for moderate-to-severe rheumatoid arthritis showed clinical
equivalence with AbbVie's Humira after 24 weeks in a phase III
study.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 23, 2015 10:11 ET (14:11 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
